Royalmount and NCI begin biomarker cancer study

Royalmount Pharma is collaborating with the NCI under a clinical trial agreement for the evaluation of the drug RM1812 as a cancer chemopreventive agent against colorectal cancer. Chemoprevention is defined as the employment of drugs or natural compounds to prevent the development of benign or malignant tumors

The tolerability, target tissue levels, biological markers of activity, and pharmacodynamics of the drug will be assessed. Eligible participants in this study are patients with colorectal cancer who will be undergoing a colorectal endoscopy.

“It is now widely accepted that the study of biological markers is important to better understand the activity of a drug and we believe that the results will assist us in the design of our future clinical trials for colorectal cancer chemoprevention and other therapeutic indications,” said Dr Tristan Booth, chief scientific officer of Royalmount Pharma.

A phase I repeat-dose clinical study to assess the safety and pharmacokinetics of RM1812 following 29-day dosing to healthy volunteers is ongoing.